Postoperative radioiodine ablation does not reduce cancer recurrence following thyroidectomy
1. The 5-year recurrence-free survival was comparable with ablation and without ablation. 2. Adverse events were comparable in both groups, ...
1. The 5-year recurrence-free survival was comparable with ablation and without ablation. 2. Adverse events were comparable in both groups, ...
1. Pembrolizumab plus radiotherapy and surgery significantly improved disease-free survival. 2. Grade 3 or higher adverse events were more common ...
1. Progression-free survival improved significantly in patients with low-volume disease who received abiraterone and radiotherapy. 2. The addition of radiotherapy ...
1. 5-year progression-free survival was increased in the induction chemotherapy group compared to standard chemoradiotherapy. 2. Patients in the induction ...
Click here to read this study in the Lancet. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
Click here to read this study in NEJM. ©2024 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced ...
1. There was no significant difference in metastasis-free survival between the ADT and non-ADT groups over 10 years. 2. Adverse ...
1. There were similar rates of ipsilateral invasive recurrence among the postoperative adjuvant radiotherapy group (group 1) and non-radiotherapy group ...
1. There were similar rates of ipsilateral invasive recurrence among the postoperative adjuvant radiotherapy group (group 1) and non-radiotherapy group ...
1. Median progression-free survival was greater in the SBRT group than in the standard-of-care group. 2. Patients with NSCLC displayed ...
2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.